Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.

@article{Paronis1993NaltrexoneIV,
  title={Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.},
  author={Carol A. Paronis and A B Waddell and Stephen G. Holtzman},
  journal={Pharmacology, biochemistry, and behavior},
  year={1993},
  volume={46 4},
  pages={813-7}
}
The ability of the competitive opioid antagonist, naltrexone, to protect opioid receptors from inactivation by the nonequilibrium antagonists, beta-funaltrexamine (beta-FNA) and nor-binaltorphimine (nor-BNI), was examined in vivo. Male rats were injected SC with 10 mg/kg naltrexone or saline, 30 min before being injected intracisternally (IC) with water, 10 micrograms beta-FNA, or 1.0 or 10 micrograms nor-BNI. The rats were tested for analgesic responses to either U69,593 (nor-BNI groups) or… CONTINUE READING